NCT00367016View on ClinicalTrials.gov

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

October 17, 2012

Study Completion Date

October 17, 2012

Conditions
AsthmaAllergic RhinitisAtopic Dermatitis
Interventions
DRUG

Omalizumab

Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.

DRUG

Placebo

Placebo, given by subcutaneous injection.

Trial Locations (1)

95816

UC Davis Department of Dermatology, Sacramento

All Listed Sponsors
lead

University of California, Davis

OTHER

NCT00367016 - Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) | Biotech Hunter | Biotech Hunter